<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9">
  <url><loc>https://peptide.zone/story/cagrisema-bone-density-calcitonin-receptor</loc><news:news><news:publication><news:name>Peptide Zone</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17T08:32:00.000Z</news:publication_date><news:title>CagriSema bone density data at ObesityWeek point to a calcitonin receptor role</news:title></news:news></url>
  <url><loc>https://peptide.zone/story/fehb-glp-1-coverage-behavioral-therapy</loc><news:news><news:publication><news:name>Peptide Zone</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17T07:56:00.000Z</news:publication_date><news:title>FEHB GLP 1 coverage for weight loss will require behavioral therapy in 2027</news:title></news:news></url>
  <url><loc>https://peptide.zone/story/karl-stefanovic-ozempic-medical-need</loc><news:news><news:publication><news:name>Peptide Zone</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17T07:01:00.000Z</news:publication_date><news:title>Karl Stefanovic Ozempic comments draw caution on weight and medical need</news:title></news:news></url>
  <url><loc>https://peptide.zone/story/glepaglutide-eu-approval-short-bowel</loc><news:news><news:publication><news:name>Peptide Zone</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17T06:31:00.000Z</news:publication_date><news:title>Glepaglutide EU approval gives short bowel syndrome a twice weekly GLP 2 drug</news:title></news:news></url>
  <url><loc>https://peptide.zone/story/mounjaro-oral-contraceptives-ema-advice</loc><news:news><news:publication><news:name>Peptide Zone</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17T06:04:00.000Z</news:publication_date><news:title>Mounjaro oral contraceptives advice tightened by EMA with a four week backup rule</news:title></news:news></url>
  <url><loc>https://peptide.zone/story/avexitide-post-bariatric-hypoglycemia-lucidity</loc><news:news><news:publication><news:name>Peptide Zone</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16T16:42:00.000Z</news:publication_date><news:title>Avexitide post bariatric hypoglycemia trial cuts serious low sugar events by 55 percent in Phase 3</news:title></news:news></url>
  <url><loc>https://peptide.zone/story/fda-naion-warning-glp-1-class</loc><news:news><news:publication><news:name>Peptide Zone</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16T16:10:00.000Z</news:publication_date><news:title>FDA NAION warning now covers every GLP 1 drug after a review of 126 trials</news:title></news:news></url>
  <url><loc>https://peptide.zone/story/ribupatide-weight-loss-gemini-1-jama</loc><news:news><news:publication><news:name>Peptide Zone</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16T15:24:00.000Z</news:publication_date><news:title>Ribupatide weight loss reaches 17.7 percent in JAMA report on Phase 3 GEMINI 1 trial in China</news:title></news:news></url>
  <url><loc>https://peptide.zone/story/berobenatide-blackstone-funding-pfizer</loc><news:news><news:publication><news:name>Peptide Zone</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16T15:02:00.000Z</news:publication_date><news:title>Berobenatide Blackstone funding gives Pfizer up to 1.5 billion dollars for monthly GLP 1 trials</news:title></news:news></url>
  <url><loc>https://peptide.zone/story/glp-1-prescriptions-children-england</loc><news:news><news:publication><news:name>Peptide Zone</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16T14:10:00.000Z</news:publication_date><news:title>GLP 1 prescriptions for children in England reach hundreds including some under 12 FOI data show</news:title></news:news></url>
</urlset>